Healthcare
10 articles
How to Trust Generic Drugs: Efficacy, Savings, and Informed Choices
A recent nationwide study in India delivered a powerful message: every single one of 131 generic medicine samples, spanning 22 essential categories, met all quality criteria.
Novo Nordisk security breach exposes patient data in cyberattack
Patient data, including sensitive medical histories from some of Novo Nordisk's clinical trials, was compromised in a recent cybersecurity breach.
Hospitals Cut Costs with Integrated Care
UVM Medical Center loses $460,000 daily, forcing 142 job cuts.
Peptide craze hype faces scientific and practical hurdles
Only 1 in 12 patients prescribed GLP-1 treatment remain on the medication after three years, according to data from Prime Therapeutics .
Medicare offers $50 monthly GLP-1 access amid obesity drug competition
Starting July 1, 2026, eligible Medicare beneficiaries will pay just $50 a month for certain GLP-1 obesity drugs.
Legend Biotech stock surges on strong Q1 CAR T-cell therapy results
Legend Biotech's stock recently jumped 42% following new data, propelled by early clinical successes in difficult-to-treat cancers and robust sales of its existing CAR-T therapy, CARVYKTI, according t
General Catalyst Acquires Summa Health for $515M, Boosting Tech Initiatives
After posting a $43.5 million operating loss in 2023, Summa Health is shedding $850 million in debt, transitioning to a for-profit entity under General Catalyst's ownership. This move sees General Cat
Bristol Myers Squibb shows strong multiple myeloma data
In a significant development for multiple myeloma patients, Bristol Myers Squibb's mezigdomide triplet demonstrated a median progression-free survival of 18 months, more than doubling the 8.
Congress cuts $1 trillion from healthcare, raising costs for millions
In January 2026, 20 million Americans saw their healthcare insurance costs jump by $1,000 a year.
Merck Halts Parkinson's Drug Program After Phase 3 Setback
Merck's Parkinson's drug, preladenant, was discontinued in 2026 after Phase 3 trials showed it was no more effective than a placebo.